This level of prophylaxis was maintained during the study (in patients with CD4<200 cells/mm3) with 83%, 53%, 59% taking anti-PCP, other anti-fungal, and antibacterial medications at the last follow-up visit respectively. This evidence concerns the gene CD4 and pneumocystosis.